CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE

Rhea-AI Summary

CASI Pharmaceuticals (Nasdaq: CASI) has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference, scheduled for September 9-11, 2024, at the Lotte New York Palace. Key members of CASI's management team, including CFO Daniel Lang and CMO Alexander Zukiwski, will be available for one-on-one investor meetings during the event.

A pre-recorded corporate presentation will be accessible to conference attendees in 'Virtual Room 1' starting at 7 a.m. Eastern Time on September 9th. Following the conference, the presentation will be made available on the Investors page of CASI's corporate website. This participation underscores CASI's commitment to engaging with investors and showcasing its progress in developing and commercializing innovative therapeutics and pharmaceutical products.

BEIJING, Sept. 4, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, today announced its participation in the H.C. Wainwright 26^th Annual Global Investment Conference taking place September 9-11, 2024, at the Lotte New York Palace in New York City. Members of the CASI management team, including Chief Financial Officer Daniel Lang, MD, and Chief Medical Officer Alexander Zukiwski, MD, will host 1x1 investor meetings at the conference.

A pre-recorded corporate presentation will be available for conference participants to view in "Virtual Room 1" at 7 a.m. Eastern Time on September 9th. Thereafter, the presentation will be available on the Investors page of the CASI corporate website at https://casipharmaceuticals.com/investor.html.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its focus on hematology oncology therapeutics and therapeutics for organ transplant rejection and autoimmune disease, as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the Greater China market, leveraging the Company's China-based regulatory and commercial competencies and its global drug development expertise. The Company's operations in China are conducted through its wholly owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd., located in Beijing, China. More information on CASI is available at www.casipharmaceuticals.com.

COMPANY CONTACT:
Rui Zhang
CASI Pharmaceuticals, Inc.
240.864.2643
ir@casipharmaceuticals.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/casi-pharmaceuticals-to-participate-in-the-2024-hc-wainwright-global-investment-conference-302237656.html

SOURCE CASI Pharmaceuticals

FAQ

When is CASI Pharmaceuticals (CASI) participating in the H.C. Wainwright Global Investment Conference?

CASI Pharmaceuticals (CASI) is participating in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024.

Where can investors view CASI's corporate presentation after the conference?

After the conference, investors can view CASI's corporate presentation on the Investors page of the CASI corporate website at https://casipharmaceuticals.com/investor.html.

Which CASI Pharmaceuticals executives will be available for investor meetings at the conference?

Chief Financial Officer Daniel Lang, MD, and Chief Medical Officer Alexander Zukiwski, MD, from CASI Pharmaceuticals will be available for one-on-one investor meetings at the conference.

What time will CASI's pre-recorded presentation be available on September 9th, 2024?

CASI's pre-recorded corporate presentation will be available for conference participants to view in 'Virtual Room 1' at 7 a.m. Eastern Time on September 9th, 2024.